SHCBP1 and Hepatic fibrosis: Given that inhibiting IL11 signaling reduces liver fibrosis and multiple pathways regulate IL11 expression, combining MCM7 or SHCBP1-RACGAP1-STAT3 axis inhibitors with existing IL11 inhibitors may achieve synergistic multi-target action, significantly attenuating or even reversing liver fibrosis progression.